SG10201502566SA - Use of novel pan-cdk inhibitors for treating tumors - Google Patents
Use of novel pan-cdk inhibitors for treating tumorsInfo
- Publication number
- SG10201502566SA SG10201502566SA SG10201502566SA SG10201502566SA SG10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA SG 10201502566S A SG10201502566S A SG 10201502566SA
- Authority
- SG
- Singapore
- Prior art keywords
- treating tumors
- cdk inhibitors
- novel pan
- pan
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010014426A DE102010014426A1 (en) | 2010-04-01 | 2010-04-01 | Use of new pan-CDK inhibitors for the treatment of tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201502566SA true SG10201502566SA (en) | 2015-05-28 |
Family
ID=43858236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012065819A SG183925A1 (en) | 2010-04-01 | 2011-03-28 | Use of novel pan-cdk inhibitors for treating tumors |
| SG10201502566SA SG10201502566SA (en) | 2010-04-01 | 2011-03-28 | Use of novel pan-cdk inhibitors for treating tumors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012065819A SG183925A1 (en) | 2010-04-01 | 2011-03-28 | Use of novel pan-cdk inhibitors for treating tumors |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20130210846A1 (en) |
| EP (1) | EP2552450A1 (en) |
| JP (1) | JP5816259B2 (en) |
| KR (1) | KR20130014678A (en) |
| CN (1) | CN102834100A (en) |
| AU (1) | AU2011234654B2 (en) |
| BR (1) | BR112012024422A2 (en) |
| CA (1) | CA2794996A1 (en) |
| CL (1) | CL2012002753A1 (en) |
| CR (1) | CR20120502A (en) |
| DE (1) | DE102010014426A1 (en) |
| DO (1) | DOP2012000260A (en) |
| EC (1) | ECSP12012198A (en) |
| MA (1) | MA34098B1 (en) |
| MX (1) | MX337722B (en) |
| NZ (1) | NZ602710A (en) |
| SG (2) | SG183925A1 (en) |
| TN (1) | TN2012000469A1 (en) |
| UA (1) | UA108494C2 (en) |
| WO (1) | WO2011120922A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201491732A1 (en) * | 2012-03-21 | 2015-08-31 | Байер Интеллектуэль Проперти Гмбх | APPLICATION (RS) -S-CYCLOPROPYL-S- (4 - {[4 - {[(1R, 2R) -2-HYDROXY-1-METHYLPROPIL] OXY} -5- (TRIFTOROMETHYL) Pyrimidine-2-IL] AMINO} PHENYL) SULPHOXIMIDE FOR THE TREATMENT OF SPECIFIC TUMORS |
| MX2015011800A (en) * | 2013-03-07 | 2016-01-08 | Bayer Pharma AG | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpr opyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfox imide for treatment of specific tumours. |
| HUE044238T2 (en) * | 2013-03-13 | 2019-10-28 | Oncoceutics Inc | 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer |
| WO2014173815A1 (en) * | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
| WO2014202583A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| WO2015071231A1 (en) * | 2013-11-14 | 2015-05-21 | Bayer Pharma Aktiengesellschaft | Combinations of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating tumours |
| CN109283279B (en) * | 2017-07-21 | 2019-11-01 | 南京正大天晴制药有限公司 | Pass through high efficiency liquid chromatography for separating and determining Raltitrexed and its method of enantiomter |
| CN109283263B (en) * | 2017-07-21 | 2019-06-25 | 南京正大天晴制药有限公司 | Determination method for Raltitrexed synthesis quality control |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4029650A1 (en) | 1990-09-19 | 1992-03-26 | Hoechst Ag | New 2-aryl:amino-pyrimidine derivs. - contg. alkynyl gp., useful as fungicides |
| EP1017394B1 (en) | 1997-07-12 | 2005-12-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| JP2002523498A (en) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | Pyrimidine compounds |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| PL367130A1 (en) | 2001-05-29 | 2005-02-21 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| JP2005526765A (en) | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | CDK-inhibiting 2-heteroaryl-pyrimidines, their production and use as pharmaceuticals |
| DE10349423A1 (en) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments |
| DE102005062742A1 (en) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | New sulfoximine-substituted pyrimidines useful for treating e.g. diseases caused by inflammatory, allergic or proliferative processes, oncological diseases, cancer, eye, autoimmune and neurodegerative diseases |
| DE102006027156A1 (en) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | New sulfimide compounds are protein kinase inhibitors useful to treat e.g. cancer, Hodgkin's lymphoma, Kaposi's sarcoma, cardiovascular disease, Crohn's disease, endometriosis and hemangioma |
| EP1878726A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| EP2179991A1 (en) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
-
2010
- 2010-04-01 DE DE102010014426A patent/DE102010014426A1/en not_active Withdrawn
-
2011
- 2011-03-28 SG SG2012065819A patent/SG183925A1/en unknown
- 2011-03-28 MA MA35265A patent/MA34098B1/en unknown
- 2011-03-28 NZ NZ602710A patent/NZ602710A/en not_active IP Right Cessation
- 2011-03-28 KR KR1020127025684A patent/KR20130014678A/en not_active Application Discontinuation
- 2011-03-28 WO PCT/EP2011/054733 patent/WO2011120922A1/en active Application Filing
- 2011-03-28 AU AU2011234654A patent/AU2011234654B2/en not_active Ceased
- 2011-03-28 JP JP2013501789A patent/JP5816259B2/en not_active Expired - Fee Related
- 2011-03-28 CN CN2011800166124A patent/CN102834100A/en active Pending
- 2011-03-28 SG SG10201502566SA patent/SG10201502566SA/en unknown
- 2011-03-28 UA UAA201212233A patent/UA108494C2/en unknown
- 2011-03-28 MX MX2012011427A patent/MX337722B/en active IP Right Grant
- 2011-03-28 EP EP11710224A patent/EP2552450A1/en not_active Withdrawn
- 2011-03-28 BR BR112012024422A patent/BR112012024422A2/en not_active IP Right Cessation
- 2011-03-28 CA CA2794996A patent/CA2794996A1/en not_active Abandoned
- 2011-03-28 US US13/638,833 patent/US20130210846A1/en not_active Abandoned
-
2012
- 2012-09-27 TN TNP2012000469A patent/TN2012000469A1/en unknown
- 2012-10-01 CL CL2012002753A patent/CL2012002753A1/en unknown
- 2012-10-01 EC ECSP12012198 patent/ECSP12012198A/en unknown
- 2012-10-01 CR CR20120502A patent/CR20120502A/en unknown
- 2012-10-01 DO DO2012000260A patent/DOP2012000260A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ602710A (en) | 2014-05-30 |
| MX337722B (en) | 2016-03-16 |
| SG183925A1 (en) | 2012-10-30 |
| CA2794996A1 (en) | 2011-10-06 |
| CN102834100A (en) | 2012-12-19 |
| BR112012024422A2 (en) | 2016-05-31 |
| DE102010014426A1 (en) | 2011-10-06 |
| WO2011120922A1 (en) | 2011-10-06 |
| EP2552450A1 (en) | 2013-02-06 |
| ECSP12012198A (en) | 2012-10-30 |
| DOP2012000260A (en) | 2013-03-31 |
| AU2011234654A1 (en) | 2012-10-25 |
| JP5816259B2 (en) | 2015-11-18 |
| CL2012002753A1 (en) | 2013-01-18 |
| MX2012011427A (en) | 2013-03-05 |
| AU2011234654B2 (en) | 2015-08-06 |
| US20130210846A1 (en) | 2013-08-15 |
| CR20120502A (en) | 2012-11-20 |
| JP2013523680A (en) | 2013-06-17 |
| KR20130014678A (en) | 2013-02-08 |
| MA34098B1 (en) | 2013-03-05 |
| TN2012000469A1 (en) | 2014-01-30 |
| UA108494C2 (en) | 2015-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276362A (en) | Methods of treating cancer | |
| HK1243919A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
| HUE060305T2 (en) | Fap-activated proteasome inhibitors for treating solid tumors | |
| EP2542081A4 (en) | Compounds for treatment of cancer | |
| EP2554175A4 (en) | Composition for treatment of damaged part | |
| HK1162916A1 (en) | Methods of treatment for solid tumors | |
| LT2523661T (en) | Nkcc inhibitors for the treatment of autism | |
| EP2643001A4 (en) | Method of treating cancer | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| HK1189272A1 (en) | Methods of treating cancer | |
| SG10201502566SA (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| EP2544692A4 (en) | Use of tigecycline for treatment of cancer | |
| EP2608671A4 (en) | Compounds for treatment of cancer | |
| IL221404A (en) | Thioxanthone-based autophagy inhibitor for treatment of cancer | |
| EP2640390A4 (en) | Methods of treating cancer | |
| EP2897607A4 (en) | Inhibitors of beta-hydrolase for treatment of cancer | |
| GB201214877D0 (en) | Compounds for treatments of tumors | |
| EP2768512A4 (en) | Enzyme inhibitor for cancer treatment | |
| WO2012037553A9 (en) | Use of pkc-iota inhibitors for the treatment of breast cancer | |
| IL231448A0 (en) | Phosphatidylinositol 3 - kinase inhibitors for the treatment of cancer | |
| GB201019034D0 (en) | Treatment for tumors |